• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SVP & CFO Singleton Mark Leonard sold $29,334 worth of shares (3,875 units at $7.57), decreasing direct ownership by 3% to 141,088 units (SEC Form 4)

    4/15/25 5:50:38 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care
    Get the next $BVS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Singleton Mark Leonard

    (Last) (First) (Middle)
    4721 EMPEROR BOULEVARD, SUITE 100

    (Street)
    DURHAM NC 27703

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Bioventus Inc. [ BVS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP & CFO
    3. Date of Earliest Transaction (Month/Day/Year)
    04/11/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 04/11/2025 S(1) 3,875 D $7.57(2) 141,088 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Reflects shares sold to cover taxes upon the vesting of restricted stock units on April 10, 2025 pursuant to a standing 10b5-1 instruction adopted on April 10, 2023.
    2. The price reported in Column 4 is a weighted average price calculated by the broker executing the sales transactions. These shares were sold as part of a trade comprised of shares of multiple employees of the Issuer in multiple transactions at prices ranging from $7.145 to $7.890, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.
    Remarks:
    /s/ Anthony D'Adamio, Attorney-in-Fact 04/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BVS

    DatePrice TargetRatingAnalyst
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    12/7/2023$7.00Hold → Buy
    Canaccord Genuity
    8/9/2023$4.00 → $6.00Hold → Buy
    Craig Hallum
    11/22/2022Buy → Hold
    Craig Hallum
    11/9/2022$18.00 → $6.00Buy → Hold
    Canaccord Genuity
    11/9/2022Overweight → Underweight
    JP Morgan
    3/15/2022$30.00Buy
    Craig Hallum
    3/11/2022$20.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP & CFO Singleton Mark Leonard sold $29,334 worth of shares (3,875 units at $7.57), decreasing direct ownership by 3% to 141,088 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      4/15/25 5:50:38 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SVP & General Counsel D'Adamio Anthony sold $22,392 worth of shares (2,958 units at $7.57), decreasing direct ownership by 2% to 131,416 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      4/15/25 5:50:10 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SVP & Chief Compliance Officer Church Katrina J sold $9,712 worth of shares (1,283 units at $7.57), decreasing direct ownership by 2% to 55,557 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      4/15/25 5:49:31 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Bioventus Inc.

      10-Q - Bioventus Inc. (0001665988) (Filer)

      5/6/25 7:38:47 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bioventus Inc. (0001665988) (Filer)

      5/6/25 7:36:54 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Bioventus Inc.

      DEFA14A - Bioventus Inc. (0001665988) (Filer)

      4/22/25 8:13:19 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      8/20/24 6:16:00 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bioventus upgraded by Analyst with a new price target

      Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously

      12/17/24 7:32:13 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Bioventus from Hold to Buy and set a new price target of $7.00

      12/7/23 6:14:32 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Bioventus from Hold to Buy and set a new price target of $6.00 from $4.00 previously

      8/9/23 7:43:55 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

      DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

      4/28/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

      DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

      2/28/25 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives.

      1/7/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      11/8/24 9:13:26 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      7/15/24 5:15:58 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Bioventus Inc. (Amendment)

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      2/14/24 4:51:41 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Financials

    Live finance-specific insights

    See more
    • Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

      DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

      4/28/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

      DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

      2/28/25 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

      DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web

      10/29/24 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Bioventus Appoints Mark Singleton as Chief Financial Officer

      DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si

      2/28/22 7:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus Appoints Michelle McMurry-Heath to Board of Directors

      DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex

      12/21/21 9:25:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care